title: Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection.
abstract: The array of human immunodeficiency virus (HIV) subtypes encountered in East London, an area long associated with migration, is unusually heterogeneous, reflecting the diverse geographical origins of the population. In this study it was shown that viral subtypes or clades infecting a sample of HIV type 1 (HIV-1)-positive individuals in East London reflect the global pandemic. The authors studied the humoral response in 210 treatment-naïve chronically HIV-1-infected (>1 year) adult subjects against a panel of 12 viruses from six different clades. Plasmas from individuals infected with clade C, but also plasmas from clade A, and to a lesser degree clade CRF02_AG and CRF01_AE, were significantly more potent at neutralizing the tested viruses compared with plasmas from individuals infected with clade B. The difference in humoral robustness between clade C- and B-infected patients was confirmed in titration studies with an extended panel of clade B and C viruses. These results support the approach to develop an HIV-1 vaccine that includes clade C or A envelope protein (Env) immunogens for the induction of a potent neutralizing humoral response.
authors.affiliation: HIV/AIDS Group, Centre for Immunology and Infectious Disease, The Blizard Institute of Cell and Molecular Science, Barts and The London, Queen Mary's School of Medicine and Dentistry, London E1 2AT, UK.
authors.forename: Hanna
authors.initials: H
authors.lastname: Dreja
authors.forename: Eithne
authors.initials: E
authors.lastname: O'Sullivan
authors.forename: Corinna
authors.initials: C
authors.lastname: Pade
authors.forename: Kelli M
authors.initials: KM
authors.lastname: Greene
authors.forename: Hongmei
authors.initials: H
authors.lastname: Gao
authors.forename: Keith
authors.initials: K
authors.lastname: Aubin
authors.forename: James
authors.initials: J
authors.lastname: Hand
authors.forename: Are
authors.initials: A
authors.lastname: Isaksen
authors.forename: Carl
authors.initials: C
authors.lastname: D'Souza
authors.forename: Werner
authors.initials: W
authors.lastname: Leber
authors.forename: David
authors.initials: D
authors.lastname: Montefiori
authors.forename: Michael S
authors.initials: MS
authors.lastname: Seaman
authors.forename: Jane
authors.initials: J
authors.lastname: Anderson
authors.forename: Chloe
authors.initials: C
authors.lastname: Orkin
authors.forename: Aine
authors.initials: A
authors.lastname: McKnight
mesh_terms: D057134:Antibodies, Neutralizing / Q000097:blood*; D015331:Cohort Studies; D005260:Female; D005838:Genotype; D015483:HIV Antibodies / Q000097:blood*; D016333:HIV Protease; D054303:HIV Reverse Transcriptase; D015497:HIV-1 / Q000145:classification* / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D008131:London; D008297:Male; D009500:Neutralization Tests; D017422:Sequence Analysis, DNA
chemical_list: D057134:Antibodies, Neutralizing; D015483:HIV Antibodies; C514824:reverse transcriptase, Human immunodeficiency virus 1; D054303:HIV Reverse Transcriptase; D016333:HIV Protease; C514803:p16 protease, Human immunodeficiency virus 1